Skip to main content .


BARDA partners with Chembio Diagnostics, Inc. to develop a point-of-care in vitro diagnostic test for the detection of SARS-CoV-2 in respiratory specimens

BARDA Response

BARDA and Chembio Diagnostics, Inc. are partnering to develop a point-of-care in vitro diagnostic test. This advanced lateral flow-based SARS-CoV-2 antigen detection test would run on the company’s proprietary platform.

Currently, there is a need for expanded point-of-care testing for COVID-19. Chembio’s proprietary DPP® Assay and DPP® Micro Reader have obtained U.S. Food and Drug Administration (FDA) clearance for several assays including Zika, Ebola, and HIV. The company plans to apply this technology to develop a rapid, easy to use COVID-19 diagnostic for the detection of SARS-CoV-2 in respiratory specimens such as nasal swabs (NS) and nasopharyngeal swabs (NP). In the event the new test is developed and receives necessary FDA approvals, Chembio expects it will be able to scale production of DPP® tests at its Hauppauge, New York facilities to increase capacity for COVID-19 diagnostic tests.


This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About the Company: 
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. The company’s proprietary DPP technology platform, which uses a small drop of blood from the fingertip or alternative sample types, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at https://chembio.com.

Last Updated: July 06, 2020

Website Refresh

www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov